# Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis

> **NCT02282982** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 359 (actual)

## Conditions studied

- Respiratory Syncytial Virus (RSV)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02282982
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 359 (ACTUAL)
- **Last updated:** 2016-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02282982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02282982, "Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT02282982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*